S&P 500   3,973.75 (+1.86%)
DOW   31,880.24 (+1.98%)
QQQ   293.48 (+1.66%)
AAPL   143.11 (+4.01%)
MSFT   260.65 (+3.20%)
FB   196.23 (+1.39%)
GOOGL   2,229.76 (+2.37%)
AMZN   2,151.14 (-0.03%)
TSLA   674.90 (+1.66%)
NVDA   168.98 (+1.22%)
BABA   87.23 (+0.51%)
NIO   16.00 (-2.68%)
AMD   95.07 (+1.68%)
CGC   5.19 (-5.98%)
MU   69.59 (+1.00%)
T   20.74 (+1.67%)
GE   75.46 (+0.28%)
F   12.83 (+2.64%)
DIS   105.83 (+3.33%)
AMC   11.58 (-3.74%)
PFE   52.88 (+0.78%)
PYPL   81.18 (+0.79%)
NFLX   187.44 (+0.58%)
S&P 500   3,973.75 (+1.86%)
DOW   31,880.24 (+1.98%)
QQQ   293.48 (+1.66%)
AAPL   143.11 (+4.01%)
MSFT   260.65 (+3.20%)
FB   196.23 (+1.39%)
GOOGL   2,229.76 (+2.37%)
AMZN   2,151.14 (-0.03%)
TSLA   674.90 (+1.66%)
NVDA   168.98 (+1.22%)
BABA   87.23 (+0.51%)
NIO   16.00 (-2.68%)
AMD   95.07 (+1.68%)
CGC   5.19 (-5.98%)
MU   69.59 (+1.00%)
T   20.74 (+1.67%)
GE   75.46 (+0.28%)
F   12.83 (+2.64%)
DIS   105.83 (+3.33%)
AMC   11.58 (-3.74%)
PFE   52.88 (+0.78%)
PYPL   81.18 (+0.79%)
NFLX   187.44 (+0.58%)
S&P 500   3,973.75 (+1.86%)
DOW   31,880.24 (+1.98%)
QQQ   293.48 (+1.66%)
AAPL   143.11 (+4.01%)
MSFT   260.65 (+3.20%)
FB   196.23 (+1.39%)
GOOGL   2,229.76 (+2.37%)
AMZN   2,151.14 (-0.03%)
TSLA   674.90 (+1.66%)
NVDA   168.98 (+1.22%)
BABA   87.23 (+0.51%)
NIO   16.00 (-2.68%)
AMD   95.07 (+1.68%)
CGC   5.19 (-5.98%)
MU   69.59 (+1.00%)
T   20.74 (+1.67%)
GE   75.46 (+0.28%)
F   12.83 (+2.64%)
DIS   105.83 (+3.33%)
AMC   11.58 (-3.74%)
PFE   52.88 (+0.78%)
PYPL   81.18 (+0.79%)
NFLX   187.44 (+0.58%)
S&P 500   3,973.75 (+1.86%)
DOW   31,880.24 (+1.98%)
QQQ   293.48 (+1.66%)
AAPL   143.11 (+4.01%)
MSFT   260.65 (+3.20%)
FB   196.23 (+1.39%)
GOOGL   2,229.76 (+2.37%)
AMZN   2,151.14 (-0.03%)
TSLA   674.90 (+1.66%)
NVDA   168.98 (+1.22%)
BABA   87.23 (+0.51%)
NIO   16.00 (-2.68%)
AMD   95.07 (+1.68%)
CGC   5.19 (-5.98%)
MU   69.59 (+1.00%)
T   20.74 (+1.67%)
GE   75.46 (+0.28%)
F   12.83 (+2.64%)
DIS   105.83 (+3.33%)
AMC   11.58 (-3.74%)
PFE   52.88 (+0.78%)
PYPL   81.18 (+0.79%)
NFLX   187.44 (+0.58%)
NASDAQ:DRTS

Alpha Tau Medical (DRTS) Stock Forecast, Price & News

$5.74
+0.33 (+6.10%)
(As of 05/23/2022 04:00 PM ET)
Add
Compare
Today's Range
$4.90
$6.39
50-Day Range
$5.19
$15.30
52-Week Range
$4.68
$20.65
Volume
58,716 shs
Average Volume
608,417 shs
Market Capitalization
$381.88 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.94
30 days | 90 days | 365 days | Advanced Chart
Receive DRTS News and Ratings via Email

Sign-up to receive the latest news and ratings for Alpha Tau Medical and its competitors with MarketBeat's FREE daily newsletter.

Alpha Tau Medical logo

About Alpha Tau Medical

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, and breast cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:DRTS
Fax
N/A
Employees
83
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
($0.86) per share

Profitability

Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$381.88 million
Optionable
Not Optionable

Company Calendar

Today
5/23/2022
Next Earnings (Estimated)
6/27/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

1.49 out of 5 stars

Medical Sector

1049th out of 1,423 stocks

Surgical & Medical Instruments Industry

107th out of 138 stocks

Analyst Opinion: 3.5Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -













Alpha Tau Medical (NASDAQ:DRTS) Frequently Asked Questions

Is Alpha Tau Medical a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alpha Tau Medical in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Alpha Tau Medical stock.
View analyst ratings for Alpha Tau Medical
or view top-rated stocks.

When is Alpha Tau Medical's next earnings date?

Alpha Tau Medical is scheduled to release its next quarterly earnings announcement on Monday, June 27th 2022.
View our earnings forecast for Alpha Tau Medical
.

What price target have analysts set for DRTS?

3 analysts have issued 1-year target prices for Alpha Tau Medical's stock. Their forecasts range from $19.00 to $21.00. On average, they expect Alpha Tau Medical's share price to reach $20.00 in the next year. This suggests a possible upside of 248.4% from the stock's current price.
View analysts' price targets for Alpha Tau Medical
or view top-rated stocks among Wall Street analysts.

Who are Alpha Tau Medical's key executives?
Alpha Tau Medical's management team includes the following people:
  • Mr. Uzi Sofer, CEO & Chairman (Age 52)
  • Mr. Raphi Levy, Chief Financial Officer (Age 37)
  • Mr. Amnon Gat, Chief Operations Officer (Age 47)
  • Mr. Ronen Segal, Chief Technology Officer (Age 49)
  • Prof. Yona Keisari, Chief Scientific Officer & Member of Scientific Advisory board (Age 75)
  • Ms. Rebecca Becker, VP of legal
  • Dr. Robert B. Den M.D., Chief Medical Officer & Member of Scientific Advisory Board (Age 43)
  • Prof. Itzhak Kelson, Chief Physics Officer & Member of Scientific Advisory Board (Age 82)
  • Ms. Yael Zeiger, Corp. Controller (Age 39)
What is Alpha Tau Medical's stock symbol?

Alpha Tau Medical trades on the NASDAQ under the ticker symbol "DRTS."

Who are Alpha Tau Medical's major shareholders?

Alpha Tau Medical's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Ergoteles LLC (0.02%), Penserra Capital Management LLC (0.01%) and Clear Street LLC (0.00%).

Which institutional investors are buying Alpha Tau Medical stock?

DRTS stock was acquired by a variety of institutional investors in the last quarter, including Ergoteles LLC, Penserra Capital Management LLC, and Clear Street LLC.

How do I buy shares of Alpha Tau Medical?

Shares of DRTS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Alpha Tau Medical's stock price today?

One share of DRTS stock can currently be purchased for approximately $5.74.

How much money does Alpha Tau Medical make?

Alpha Tau Medical has a market capitalization of $381.88 million.

How many employees does Alpha Tau Medical have?

Alpha Tau Medical employs 83 workers across the globe.

What is Alpha Tau Medical's official website?

The official website for Alpha Tau Medical is healthcarecapitalcorp.com.

How can I contact Alpha Tau Medical?

Alpha Tau Medical's mailing address is 301 N. MARKET STREET STE 1414, WILMINGTON DE, 19801. The company can be reached via phone at 561-810-0031 or via email at [email protected].

This page was last updated on 5/23/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.